tirzepatide surpass trials cardiovascular outcomes trial results august 2025 Matches Dulaglutide in Large CV Trial: SURPASS-CVOT Tirzepatide Improves HFpEF Symptoms and – An Observational Study of Cardiovascular – Incidence of mild and severe

Red flags include persistent vomiting, severe abdominal bloating or pain, constipation lasting several days without relief, or unintended and significant weight loss

Follow-up cadence

These readers serve as critical bridges, transmitting the modification signal to downstream functions

The researchers examined 84 people with obesity or other weight management issues

For example, a patient who typically injects on Monday mornings in New York and travels to London (five hours ahead) might inject on Monday morning before departure and continue Monday injections in London, effectively maintaining the same weekly schedule despite the time difference